T. Rowe Price Associates
EXAS

T. Rowe Price Associates’s Exact Sciences EXAS Stock Holding History

T. Rowe Price Associates’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-168,554
Closed -$17.1M – 3157
2025
Q4 		$17.1M Sell
168,554
-1,554,145
-90% -$125M ﹤0.01% 1095
2025
Q3 		$94.2M Sell
1,722,699
-1,980,566
-53% -$99M 0.01% 633
2025
Q2 		$197M Sell
3,703,265
-2,700,607
-42% -$137M 0.02% 433
2025
Q1 		$277M Buy
6,403,872
+643,631
+11% +$32.6M 0.03% 360
2024
Q4 		$324M Buy
5,760,241
+2,462,165
+75% +$153M 0.04% 339
2024
Q3 		$225M Buy
3,298,076
+2,112,953
+178% +$119M 0.03% 416
2024
Q2 		$50.1M Sell
1,185,123
-160,115
-12% -$8.81M 0.01% 724
2024
Q1 		$92.9M Sell
1,345,238
-99,410
-7% -$6.29M 0.01% 568
2023
Q4 		$107M Sell
1,444,648
-238,686
-14% -$15.6M 0.01% 530
2023
Q3 		$115M Sell
1,683,334
-498,552
-23% -$42.3M 0.02% 489
2023
Q2 		$205M Buy
2,181,886
+402,314
+23% +$31.4M 0.03% 388
2023
Q1 		$121M Sell
1,779,572
-3,212,795
-64% -$207M 0.02% 477
2022
Q4 		$247M Sell
4,992,367
-821,810
-14% -$33.6M 0.04% 335
2022
Q3 		$189M Sell
5,814,177
-9,608,207
-62% -$396M 0.03% 369
2022
Q2 		$607M Sell
15,422,384
-3,757,848
-20% -$201M 0.08% 253
2022
Q1 		$1.34B Buy
19,180,232
+5,392,099
+39% +$394M 0.14% 153
2021
Q4 		$1.07B Sell
13,788,133
-4,716,911
-25% -$416M 0.1% 208
2021
Q3 		$1.77B Sell
18,505,044
-1,284,299
-6% -$136M 0.17% 126
2021
Q2 		$2.46B Buy
19,789,343
+1,495,404
+8% +$178M 0.23% 96
2021
Q1 		$2.41B Buy
18,293,939
+1,745,691
+11% +$239M 0.24% 93
2020
Q4 		$2.19B Sell
16,548,248
-3,499,330
-17% -$423M 0.23% 98
2020
Q3 		$2.04B Sell
20,047,578
-1,401,053
-7% -$121M 0.24% 89
2020
Q2 		$1.86B Sell
21,448,631
-333,955
-2% -$26.7M 0.23% 90
2020
Q1 		$1.26B Buy
21,782,586
+3,083,995
+16% +$250M 0.2% 110
2019
Q4 		$1.73B Buy
18,698,591
+7,079,210
+61% +$622M 0.22% 101
2019
Q3 		$1.05B Buy
11,619,381
+4,434,780
+62% +$505M 0.15% 150
2019
Q2 		$848M Sell
7,184,601
-1,108,575
-13% -$112M 0.12% 190
2019
Q1 		$718M Sell
8,293,176
-1,565,146
-16% -$133M 0.11% 204
2018
Q4 		$622M Sell
9,858,322
-1,042,185
-10% -$71.5M 0.11% 201
2018
Q3 		$860M Buy
10,900,507
+4,297,878
+65% +$280M 0.13% 179
2018
Q2 		$395M Buy
6,602,629
+6,552,486
+13,068% +$353M 0.06% 308
2018
Q1 		$2.02M Buy
50,143
+12,770
+34% +$623K ﹤0.01% 1571
2017
Q4 		$1.96M Buy
37,373
+50
+0.1% +$2.67K ﹤0.01% 1590
2017
Q3 		$1.76M Buy
37,323
+15
+0% +$604 ﹤0.01% 1605
2017
Q2 		$1.32M Sell
37,308
-199,434
-84% -$6.16M ﹤0.01% 1677
2017
Q1 		$5.59M Sell
236,742
-2,258
-0.9% -$44.7K ﹤0.01% 1415
2016
Q4 		$3.19M Sell
239,000
-23,700
-9% -$383K ﹤0.01% 1474
2016
Q3 		$4.88M Buy
262,700
+6,000
+2% +$106K ﹤0.01% 1432
2016
Q2 		$3.15M Buy
256,700
+20,500
+9% +$154K ﹤0.01% 1455
2016
Q1 		$1.59M Sell
236,200
-306,900
-57% -$1.96M ﹤0.01% 1578
2015
Q4 		$5.01M Buy
543,100
+46,000
+9% +$428K ﹤0.01% 1418
2015
Q3 		$8.94M Sell
497,100
-14,000
-3% -$322K ﹤0.01% 1334
2015
Q2 		$15.2M Buy
511,100
+10,500
+2% +$264K ﹤0.01% 1227
2015
Q1 		$11M Buy
500,600
+3,000
+0.6% +$76.1K ﹤0.01% 1312
2014
Q4 		$13.7M Buy
497,600
+80,700
+19% +$1.96M ﹤0.01% 1237
2014
Q3 		$8.08M Sell
416,900
-312,800
-43% -$5.74M ﹤0.01% 1358
2014
Q2 		$12.4M Buy
729,700
+701,500
+2,488% +$9.66M ﹤0.01% 1263
2014
Q1 		$400K Sell
28,200
-8,600
-23% -$116K ﹤0.01% 2014
2013
Q4 		$430K Buy
+36,800
New +$422K ﹤0.01% 1974

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

T. Rowe Price Associates's EXAS Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 168,554 shares — an estimated $17.1M sold.

T. Rowe Price Associates first reported a position in EXAS in Q4 2013 and held it in 49 quarters. The position peaked at $2.46B in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 168,554 Exact Sciences shares in Q1 2026, an estimated $17.1M.
  • T. Rowe Price Associates first reported a position in Exact Sciences in Q4 2013 and held it in 49 quarters.
  • T. Rowe Price Associates's Exact Sciences position peaked at $2.46B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.